BioPharma DiveOriginal article
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
Phase 3positiveEpkinlyPositive
AI Analysis
Summary
AbbVie and Genmab's Epkinly achieved better-than-expected results in a frontline lymphoma trial for newly diagnosed DLBCL, potentially establishing it as the new treatment standard in this indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Better-than-expected results in frontline lymphoma trial
Importance:7/10
Sentiment:
0.75
oncologylymphomaDLBCLcombination therapyfrontline treatment
Read the original article
Published by BioPharma Dive on October 6, 2026 3:42 PM